Naturally Occurring T Regulatory Cells Control Airway Hyperresponsiveness

天然存在的 T 调节细胞控制气道高反应性

基本信息

  • 批准号:
    7910663
  • 负责人:
  • 金额:
    $ 46.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-15 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In susceptible individuals, asthma is a complex disease characterized by heightened responses to relatively innocuous antigens encountered via the respiratory tract. In a shift in thinking away from simple imbalances in Th2 and Th1 responses, there is increasing evidence for a protective role for regulatory T cells in allergic disease where they exhibit control over effector Th1 and Th2 cells. Naturally-occurring CD4+CD25+Foxp3+ regulatory cells (nTregs) isolated from the lungs of naive mice and transferred intratracheally into sensitized recipients prior to challenge suppress all aspects of lung allergic responses including airway hyperresponsiveness (AHR), airway eosinophilia, Th2 cytokine production, and goblet cell metaplasia. Conversely, depletion of these cells with anti-CD25 enhanced all of these responses. Our data indicate that the suppressive phenotype of nTregs is dependent on CD8- MHC I interactions and their production of IL-10 and TGF2. In the absence of CD8-MHC I interactions, the phenotype of the nTregs converts to one which enhances the development of lung allergic responses, and is associated with increased IL-13 production and decreased Foxp3 expression. By contrast, signaling through the glucocorticoid inducible tumor necrosis factor receptor (GITR) attenuates the suppressive phenotype. We will define the role of these nTregs in regulating mast cell-dependent and -independent AHR and whether they are responsible for the tolerant state induced by repeated allergen challenge. Using biochemical tools, genetic manipulation and in vitro and in vivo approaches, we will define the underlying mechanisms whereby CD8-MHC I interactions signal and maintain Foxp3 expression and the suppressive phenotype, and determine how signaling through GITR-GITR-ligand attenuates suppression, subverting and converting nTregs to an enhancing phenotype, characterized by Th2 cytokine production. In these approaches, we will delineate the counter-regulatory signals provided through Foxp3 and GITR and the interplay between these two defining events that appear to govern the fate (suppressive or enhancing phenotype) of nTregs. For the first time, these studies will identify the indispensable role and mechanism whereby Foxp3+nTregs control the development of lung allergic responses in sensitized hosts exposed to allergen challenge. Elucidation of the molecular basis for the functional activation of nTregs and the underlying mechanisms dictating nTreg-mediated suppression or nTreg conversion to an enhancing phenotype will form the basis for the control of their function in diseases such as asthma. PUBLIC HEALTH RELEVANCE: Asthma now afflicts more than 30 million Americans and despite the introduction of new therapies, morbidity and mortality continue to increase. If we are to impact this disease, a greater understanding of the mechanisms underlying asthma progression, delineation of the regulatory pathways, and identification of new strategies are required. This proposal addresses novel pathways that may regulate airway hyperresponsiveness and inflammation, with the potential of revealing novel and important therapeutic strategies.
描述(申请人提供):在易感个体中,哮喘是一种复杂的疾病,其特征是对通过呼吸道遇到的相对无害的抗原反应增强。随着思维从Th2和Th1反应的简单失衡转向,越来越多的证据表明,调节性T细胞在变态反应性疾病中发挥保护作用,它们表现出对效应者Th1和Th2细胞的控制。从幼鼠肺部分离的自然产生的CD4+CD25+Foxp3+调节细胞(NTregs)在激发前经气管内转移到致敏受体体内,可抑制肺过敏反应的各个方面,包括气道高反应性(AHR)、气道嗜酸性粒细胞增多、Th2细胞因子产生和杯状细胞化生。相反,用抗CD25抗体去除这些细胞会增强所有这些反应。我们的数据表明,nTregs的抑制表型依赖于CD8-MHC I相互作用及其产生的IL-10和TGF2。在缺乏CD8-MHC I相互作用的情况下,nTregs的表型转化为促进肺过敏反应的发展,并与IL-13产生增加和Foxp3表达减少有关。相反,通过糖皮质激素诱导的肿瘤坏死因子受体(GITR)传递信号可以减弱抑制表型。我们将确定这些nTregs在调节肥大细胞依赖和非依赖AHR中的作用,以及它们是否对反复过敏原刺激诱导的耐受状态负责。利用生化工具、基因操作以及体外和体内方法,我们将确定CD8-MHC I相互作用传递和维持Foxp3表达和抑制表型的潜在机制,并确定通过GITR-GITR配体传递的信号如何减弱抑制、颠覆nTregs并将其转化为以Th2细胞因子产生为特征的增强表型。在这些方法中,我们将描述通过Foxp3和GITR提供的反调控信号,以及这两个决定性事件之间的相互作用,这两个事件似乎控制着nTregs的命运(抑制或增强表型)。这些研究将首次确定Foxp3+nTregs在致敏宿主暴露于变应原攻击时控制肺过敏反应发展的不可或缺的作用和机制。阐明nTregs功能激活的分子基础,以及nTreg介导的抑制或nTreg转换为增强表型的潜在机制,将为控制其在哮喘等疾病中的功能奠定基础。与公共卫生相关:哮喘目前困扰着3000多万美国人,尽管引入了新的治疗方法,但发病率和死亡率仍在继续上升。如果我们要影响这种疾病,就需要更好地了解哮喘进展的机制,描绘调控途径,并确定新的策略。这项建议涉及可能调节呼吸道高反应性和炎症的新途径,具有揭示新的和重要的治疗策略的潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ERWIN William GELFAND其他文献

ERWIN William GELFAND的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ERWIN William GELFAND', 18)}}的其他基金

LTB4-BLT1 Interactions in the Pathogenesis of Allergic Airway Disease
LTB4-BLT1 相互作用在过敏性气道疾病发病机制中的作用
  • 批准号:
    8147497
  • 财政年份:
    2010
  • 资助金额:
    $ 46.89万
  • 项目类别:
Administrative Core A
行政核心A
  • 批准号:
    8147505
  • 财政年份:
    2010
  • 资助金额:
    $ 46.89万
  • 项目类别:
Antenatal Dietary Supplementation is a Risk Factor for Infant Atopy Through Epige
Epige 发现产前膳食补充剂是婴儿特应性的危险因素
  • 批准号:
    7821778
  • 财政年份:
    2009
  • 资助金额:
    $ 46.89万
  • 项目类别:
Antenatal Dietary Supplementation is a Risk Factor for Infant Atopy Through Epige
Epige 发现产前膳食补充剂是婴儿特应性的危险因素
  • 批准号:
    7942064
  • 财政年份:
    2009
  • 资助金额:
    $ 46.89万
  • 项目类别:
Naturally Occurring T Regulatory Cells Control Airway Hyperresponsiveness
天然存在的 T 调节细胞控制气道高反应性
  • 批准号:
    7729164
  • 财政年份:
    2009
  • 资助金额:
    $ 46.89万
  • 项目类别:
Naturally Occurring T Regulatory Cells Control Airway Hyperresponsiveness
天然存在的 T 调节细胞控制气道高反应性
  • 批准号:
    8310977
  • 财政年份:
    2009
  • 资助金额:
    $ 46.89万
  • 项目类别:
Naturally Occurring T Regulatory Cells Control Airway Hyperresponsiveness
天然存在的 T 调节细胞控制气道高反应性
  • 批准号:
    8503580
  • 财政年份:
    2009
  • 资助金额:
    $ 46.89万
  • 项目类别:
Naturally Occurring T Regulatory Cells Control Airway Hyperresponsiveness
天然存在的 T 调节细胞控制气道高反应性
  • 批准号:
    8085839
  • 财政年份:
    2009
  • 资助金额:
    $ 46.89万
  • 项目类别:
Naturally occurring T regulatory cells control airway hyperresponsiveness
天然存在的 T 调节细胞控制气道高反应性
  • 批准号:
    7683378
  • 财政年份:
    2008
  • 资助金额:
    $ 46.89万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    7255196
  • 财政年份:
    2007
  • 资助金额:
    $ 46.89万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 46.89万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 46.89万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 46.89万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 46.89万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 46.89万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 46.89万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 46.89万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 46.89万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 46.89万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 46.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了